Systematic review and meta-analysis of the utility of long non-coding RNA GAS5 as a diagnostic and prognostic cancer biomarker.
Systematic review and meta-analysis of the utility of long non-coding RNA GAS5 as a diagnostic and prognostic cancer biomarker.
复制标题
长链非编码 RNA GAS5 作为诊断和预后癌症生物标志物用途的系统回顾和荟萃分析
DOI：
10.18632/oncotarget.19040
复制
发表时间：
2017-09-12
期刊：
影响因子：
--
通讯作者：
Chen Q
中科院分区：
文献类型：
--
作者：
Li W;Li N;Shi K;Chen Q
生长停滞特异性5转录物（GAS 5）是一种长链非编码RNA（lncRNA），参与多种细胞中细胞周期进程和凋亡的控制。为了确定GAS 5表达在癌症患者中的临床价值，我们进行了系统回顾和荟萃分析，探讨其与癌症诊断、预后和临床病理特征的关系。分析了10篇关于预后的文章，15篇关于临床病理学的文章，5篇关于诊断的文章。总体结果显示，在几种肿瘤类型中，GAS 5表达降低与不利的总生存期（OS）（HR = 2.50，95%CI：1.85-3.38，P < 0.001）和无病生存期（DFS）（HR = 2.24，95%CI：1.58-3.18，P < 0.001）相关。肝细胞癌中GAS 5表达下调与低无复发生存率相关（HR = 2.40，95%CI：1.27-4.54，P = 0.007），与淋巴结转移有关（OR = 1.92，95%CI：1.44-2.57，P < 0.001），远处转移（OR = 2.7，95%CI：1.05-6.97，P = 0.040），临床分期差（OR = 0.26，95%CI：0.18-0.38，P < 0.001），肿瘤较大（OR = 3.21，95% CI：2.08-4.95，P < 0.001），肿瘤分化差（OR = 1.98，95% CI：1.40-2.80，P < 0.001）。诊断数据分析的汇总结果显示，GAS 5对癌症诊断的敏感性为0.76，特异性为0.64，曲线下面积为0.76（95%CI：0.72-0.80），表明诊断准确性中等。这项荟萃分析表明，GAS 5 lncRNA可能是一种有用的诊断和预后癌症生物标志物，并且可能特别适用于识别易于发展淋巴结或远处转移的患者。
The growth arrest-specific 5 transcript (GAS5) is a long non-coding RNA (lncRNA) involved in the control of cell cycle progression and apoptosis in a wide variety of cells. To determine the clinical value of GAS5 expression in cancer patients, we performed a systematic review and meta-analysis exploring its association with the diagnosis, prognosis, and clinicopathological characteristics of cancer. Ten articles on prognosis, 15 on clinicopathology, and 5 on diagnosis were analyzed. Overall results showed that decreased GAS5 expression associated with unfavorable overall survival (OS) (HR = 2.50, 95%CI: 1.85–3.38, P < 0.001) and disease-free survival (DFS) (HR = 2.24, 95%CI: 1.58–3.18, P < 0.001) in several tumor types. Down-regulation of GAS5 correlated with poor recurrence-free survival (RFS) in hepatocellular carcinoma (HR = 2.40, 95%CI: 1.27–4.54, P = 0.007), and was associated with lymph node metastasis (OR = 1.92, 95% CI: 1.44–2.57, P < 0.001), distant metastasis (OR = 2.7, 95% CI: 1.05–6.97, P = 0.040), poor clinical stage (OR = 0.26, 95% CI: 0.18–0.38, P < 0.001), larger tumor size (OR = 3.21, 95% CI: 2.08–4.95, P < 0.001), and poor tumor differentiation (OR = 1.98, 95% CI: 1.40–2.80, P < 0.001). Pooled results of diagnostic data analysis showed that GAS5 exhibited a sensitivity of 0.76 and specificity of 0.64 for cancer diagnosis, and an area under the curve of 0.76 (95% CI: 0.72–0.80) indicated moderate diagnostic accuracy. This meta-analysis suggests GAS5 lncRNA may be a useful diagnostic and prognostic cancer biomarker, and may be especially useful for identifying patients prone to developing lymph node or distant metastasis.